-
1
Partnering on vaccines to counter multi-drug resistant threats: Workshop proceedings, Biomedical Advanced Research and Development Authority
Published 2022-11-01“…On March 12, 2021, the Biomedical Advanced Research and Development Authority (BARDA) sponsored a virtual market research workshop, “Partnering on Vaccines to Counter Multi-Drug Resistant Threats,” to discuss the threat of antimicrobial resistance in the context of BARDA’s mission space and the challenges encountered during the development of vaccines for specific antimicrobial resistant bacteria. …”
Get full text
Article -
2
Developing Vaccines to Improve Preparedness for Filovirus Outbreaks: The Perspective of the USA Biomedical Advanced Research and Development Authority (BARDA)
Published 2023-06-01“…During the recent outbreak of SUDV virus disease, the Biomedical Advanced Research and Development Authority (BARDA), as part of the Administration for Strategic Preparedness and Response within the U.S. …”
Get full text
Article -
3
-
4
Blood product use for radiological/nuclear trauma: product development and US regulatory considerations
Published 2024-01-01Get full text
Article -
5
-
6
-
7
-
8
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Published 2023-03-01Get full text
Article -
9
Utilization of Viral Vector Vaccines in Preparing for Future Pandemics
Published 2022-03-01Get full text
Article -
10
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Published 2023-01-01Get full text
Article -
11
The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps
Published 2022-07-01Get full text
Article -
12
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Published 2023-03-01Get full text
Article -
13
Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax
Published 2023-12-01Get full text
Article -
14
Selection of Filovirus Isolates for Vaccine Development Programs
Published 2021-09-01Get full text
Article -
15
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report
Published 2023-04-01“…On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” …”
Get full text
Article -
16
-
17
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward
Published 2020-04-01Get full text
Article -
18
-
19
Natural History of Marburg Virus Infection to Support Medical Countermeasure Development
Published 2022-10-01“…The Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. …”
Get full text
Article -
20